Screener
BridgeBio Pharma BBIO Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts receivable, net | 205,226 | 139,444 |
| Inventories | 32,980 | 26,753 |
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
| Equity method investments | 61,529 | 79,972 |
| Property and equipment, net | 4,941 | 5,366 |
| Operating lease right-of-use assets | 17,226 | 8,149 |
| Intangible assets, net | 27,359 | 28,077 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total current assets?
- BridgeBio Pharma (BBIO) reported total current assets of $1.24B in Q1 2026.
- How has BridgeBio Pharma's total current assets changed year-over-year?
- BridgeBio Pharma's total current assets increased by 78.6% year-over-year, from $695.17M to $1.24B.
- What is the long-term trend for BridgeBio Pharma's total current assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total current assets has grown at a 4.4% compound annual growth rate (CAGR), from $642.82M to $797.75M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about BridgeBio Pharma's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude